Recall that shareholder-activity hedge fund investor Carl Icahn last year waged a battle with the board of Biogen--and won. In December the board replaced its chairman, and this week the CEO stepped down. Icahn had been able to get two new directors appointed.

Reuters says he may now be setting his sights on another biotech firm Genzyme. Icahn bought 1.5 million Genzyme shares in the third quarter. Genzyme may already be fighting back. It has announced an agreement with another activist investor, Ralph Whitworth. The agreement gives Whitworth, of Relational Investors, the right to join Genzyme's board. He has announced he will support and recommend each of Genzyme's board nominees at shareholder meetings. 

For more:
- here's the article

Related Articles:
Icahn vs. the Welches on board culpability
Icahn growls at CIT board